Debt-to-equity of Cogent Biosciences, Inc. from 30 Sep 2018 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Cogent Biosciences, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2018 to 30 Sep 2025.
  • Cogent Biosciences, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 41%, a 136% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Cogent Biosciences, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 41% +23% +136% 30 Sep 2025
Q2 2025 34% +18% +114% 30 Jun 2025
Q1 2025 23% +7% +46% 31 Mar 2025
Q4 2024 18% +1% +8.7% 31 Dec 2024
Q3 2024 17% +1% +7.4% 30 Sep 2024
Q2 2024 16% +1% +5.8% 30 Jun 2024
Q1 2024 15% 0% -2.7% 31 Mar 2024
Q4 2023 17% +2% +17% 31 Dec 2023
Q3 2023 16% +4% +29% 30 Sep 2023
Q2 2023 15% +4% +38% 30 Jun 2023
Q1 2023 16% +7% +82% 31 Mar 2023
Q4 2022 14% +7% +97% 31 Dec 2022
Q3 2022 12% +5% +77% 30 Sep 2022
Q2 2022 11% +1% +8.4% 30 Jun 2022
Q1 2022 9% -5% -36% 31 Mar 2022
Q4 2021 7% -18% -71% 31 Dec 2021
Q3 2021 7% -115% -94% 30 Sep 2021
Q2 2021 10% -58% -85% 30 Jun 2021
Q1 2021 14% -58% -81% 31 Mar 2021
Q4 2020 25% -47% -65% 31 Dec 2020
Q3 2020 122% +57% +86% 30 Sep 2020
Q2 2020 68% +16% +29% 30 Jun 2020
Q1 2020 71% +28% +63% 31 Mar 2020
Q4 2019 73% -2% -2.4% 31 Dec 2019
Q3 2019 65% -233% -78% 30 Sep 2019
Q2 2019 53% 30 Jun 2019
Q1 2019 44% 31 Mar 2019
Q4 2018 74% 31 Dec 2018
Q3 2018 298% 30 Sep 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.